Nal-IRI and 5-FU Compared to 5-FU in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated With Gemcitabine-based Therapies

• Status: Recruiting
• Trial end date: 2022-01-01

Summary

is an open label, randomized, multicenter phase II trial

• Phase: Phase 2

Details

• Lead Sponsor: AIO-Studien-gGmbH
• Collaborators: Servier; Shire
• Treatments: Fluorouracil; Gemcitabine; Leucovorin